Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847346 | 0.84 | POLB (0.33) | POLB | |
| SCHEMBL5842502 | 0.82 | POLB (0.31) | POLB | |
| SCHEMBL5846864 | 0.75 | MEN1 (0.30) | — | |
| SCHEMBL7127011 | 0.74 | — | — | |
| SCHEMBL5845220 | 0.73 | — | — | |
| SCHEMBL5843730 | 0.72 | POLB (0.45) | POLBCYP3A4ALOX15 | |
| SCHEMBL7585219 | 0.66 | GABRA1 (0.32) | — | |
| SCHEMBL8980275 | 0.66 | — | — | |
| SCHEMBL6688506 | 0.65 | — | — | |
| SCHEMBL7586358 | 0.65 | OSBP (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115657-B2 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2006-10-03 | — | — | US | disclosed |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | disclosed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | disclosed |
| EP-1301504-A1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004438-A1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | GPX4, GSR, GPX1 | POLB 1540/4885CYP3A4 462/4885ALOX15 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.